PTX3 and rheumatoid arthritis: Studies have specified that RA patients with CAD have increased levels of terminal complement complexes, pentraxin 3 (mediator of the alternative pathway of complement activation), and important infiltration with mononuclear cells in the vessel wall compared with patients without RA [96].